Warrant to Purchase Shares of Common Stock



 Exhibit 4.2 
 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR
OTHER DISPOSITION OF THE WARRANT REPRESENTED BY THIS CERTIFICATE OR THE UNDERLYING SECURITIES MAY BE MADE EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, AND THE RULES AND REGULATIONS IN EFFECT THEREUNDER AND ALL
APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS (SUCH FEDERAL AND STATE LAWS, THE “SECURITIES LAWS”) OR (B) IF THE CORPORATION HAS BEEN FURNISHED WITH AN OPINION OF COUNSEL FOR THE HOLDER, WHICH OPINION AND COUNSEL
SHALL BE REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT SUCH TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION IS EXEMPT FROM THE PROVISIONS OF THE SECURITIES LAWS. 

PUMA BIOTECHNOLOGY, INC. 
 WARRANT TO PURCHASE SHARES OF COMMON STOCK 
  

			
	No. CS-B 1	 	Dated: October 4, 2011

 THIS CERTIFIES THAT, for value
received, ALAN H. AUERBACH, with his principal address at 10940 Wilshire Boulevard, Suite 600, Los Angeles, California 90024, or his assigns (the “Holder”), is entitled to
subscribe for and purchase from PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Company”), the Warrant Shares (as defined below) at a price per share equal to the
Exercise Price (as defined below), on the terms and subject to the conditions contained herein only if a Subsequent Financing occurs. 
 This warrant (this “Warrant”) is being issued pursuant to that certain Securities Purchase Agreement, dated October 4, 2011, by and among the Company and the persons listed on
Schedule I attached thereto (the “Purchase Agreement”). 
 1. DEFINITIONS. The
following terms, as used herein, have the following meanings: 
 “Acquisition” means any
sale, assignment, transfer or other disposition of all or substantially all of the assets of the Company, or any reorganization, consolidation, merger, or sale of outstanding equity securities of the Company by the holders thereof, where the holders
of the Company’s outstanding voting equity securities as of immediately before such transaction beneficially own less than a majority of the outstanding voting equity securities of the surviving or successor entity as of immediately after such
transaction. 
 “Common Stock” means the common stock, par value $0.0001 per share, of
the Company. 
 “Company Options” means options to acquire shares of the Common Stock
that have been issued pursuant to the Company’s 2011 Incentive Award Plan. 

  
 1 








 “Convertible Securities” shall mean any bonds,
debentures, notes or other evidences of indebtedness, and any warrants, shares or any other securities convertible into, exercisable for, or exchangeable for Common Stock. 

“Exercise Price” means the price at which a share of Common Stock is sold in the Subsequent
Financing or, if Convertible Securities are sold in the Subsequent Financing, the per share conversion, exercise or exchange price of such Convertible Security (in each case, as adjusted for any subsequent stock splits, combinations, reorganizations
or similar transactions). 
 “Expiration Date” means the date that is ten (10) years
from the date of issuance hereof. 
 “Ownership Percentage” shall be calculated, as of
any date, by dividing (i) the total number of shares of Common Stock owned by Holder at such date (including shares of Common Stock and Convertible Securities sold, transferred or assigned by Holder prior to such date), by (ii) the total
number of shares of Common Stock issued and outstanding at such date (including, for purposes of both (i) and (ii) above, any shares issuable upon exercise or conversion of any outstanding Convertible Securities, but excluding outstanding
Company Options and any shares that have been issued upon the exercise of Company Options, but further excluding for purposes of (ii) above, all shares of Common Stock and Convertible Securities outstanding at such date to the extent issued by
the Company in any transaction closing after the date hereof that would have constituted a Subsequent Financing but for the amount of gross cash proceeds received by the Company in such transaction). 

“Subsequent Financing” means the first additional offering of the Company’s securities
resulting in gross cash proceeds to the Company of at least $15 million that closes subsequent to the closings of the Merger (as defined in the Purchase Agreement) and the PIPE (as defined in the Purchase Agreement). For purposes of determining the
occurrence of a Subsequent Financing, none of the following issuances shall be considered the issuance or sale of the Company’s securities: 
  

	 	•	 	 the issuance of Common Stock upon the conversion of any then-outstanding Convertible Securities; 



 

	 	•	 	 the issuance of any Common Stock or Convertible Securities as a dividend on the Company’s stock; 



 

	 	•	 	 the issuance of up to 3,529,412 (as adjusted for any subsequent stock splits, combinations, reorganizations or similar transactions ) shares of Common
Stock (or options to purchase shares of Common Stock) to employees, directors or consultants of the Company under the Company’s 2011 Incentive Award Plan; and 



 

	 	•	 	 the issuance of shares of Common Stock or Convertible Securities to lenders, financial institutions, equipment lessors, or real estate lessors to the
Company in connection with a bona fide borrowing or leasing transaction (and 



  
 2 









	 	 
expressly excluding any equity financing transactions) approved by the Company’s Board of Directors. 



“Trading Day” means a day on which the Company’s Common Stock is traded on any
over-the-counter market (including, without limitation, the OTCBB, OTCQX or the Pink Sheets) or listed for quotation on any national securities exchange or trading system. 

“Warrant Shares” means the number of shares of the Common Stock as would be necessary for the
Holder to acquire in order to achieve an Ownership Percentage of 20%, as calculated immediately following the closing of the Subsequent Financing (such number of shares to be adjusted for any subsequent stock splits, combinations, reorganizations or
similar transactions). 
 2. EXERCISE AND DURATION.

 2.1 The Holder may exercise this Warrant, on any business day, for all of the Warrant Shares
purchasable hereunder, from and after the first business day following the closing of the Subsequent Financing to and including the Expiration Date. 
 2.2 This Warrant shall be exercisable only by (i) the delivery to the Company at its address listed on the signature page hereto (or at such other address as it may designate by notice in
writing to the Holder) of this Warrant together with an executed Notice of Exercise in the form attached hereto (an “Exercise Notice”), and (ii) payment of the Exercise Price in one of the following manners: 

(a) Cash Exercise. The Holder may deliver immediately available funds (either in cash or by check), or by
cancellation of indebtedness. 
 (b) Cashless Exercise. If an Exercise Notice is delivered at a
time when a registration statement permitting the Holder to resell the Warrant Shares is not then effective or the prospectus forming a part thereof is not then available to the Holder for the resale of the Warrant Shares, then the Holder may notify
the Company in an Exercise Notice of its election to utilize cashless exercise, in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows: 

X = Y [(A-B)/A] 

where: 
 X = the
number of Warrant Shares to be issued to the Holder. 
 Y = the number of Warrant Shares with respect to which this Warrant is
being exercised. 
 A = the average of the closing prices for the five Trading Days immediately prior to (but not including) the
exercise date; provided, however, that if there is no public market for the Company’s Common Stock on the exercise date, then the value of 

  
 3 








 
“A” shall be equal to the then fair market value of a share of Company Common Stock as determined in good faith by the Company’s Board of Directors. 

B = the Exercise Price. 
 For purposes of Rule 144 promulgated under the Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to have been acquired by
the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued. 
 2.3 Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Common Stock so purchased, registered in the name of the Holder or persons affiliated with the
Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 

2.4 The person in whose name any certificate or certificates for shares of Common Stock are to be issued upon
exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or
certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next
succeeding date on which the stock transfer books are open. 
 3. COVENANTS OF
THE COMPANY. 
 3.1 Covenants as to Common Stock. The Company covenants
and agrees that all Common Stock that may be issued upon the exercise of the rights represented by this Warrant, will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with
respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times, until the rights under this Warrant are no longer exercisable, have authorized and reserved, free from preemptive rights, a sufficient
number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time during the period at which the rights under this Warrant are exercisable, the number of authorized but unissued shares of Common
Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares
as shall be sufficient for such purposes. 
 3.2 No Impairment. The Company will not, by amendment of its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to


  
 4 








 
protect the exercise rights of the Holder against impairment. The Company will not increase the par value of the Common Stock in excess of the Exercise Price for the Warrant. 

3.3 Acquisition. Upon the closing of any Acquisition, the surviving or successor entity shall assume this Warrant
and the obligations of the Company hereunder, and this Warrant shall, from and after such closing, be exercisable for the same class, number and kind of securities, cash and other property as would have been paid for or in respect of shares of
Common Stock in connection with such Acquisition, at an aggregate exercise price equal to the aggregate Exercise Price in effect as of immediately prior to such closing. 
 4. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the
Company. 
 5. TRANSFER OF WARRANT. Subject to applicable laws and
the restriction on transfer set forth on the first page of this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment
attached hereto to any transferee designated by Holder. The Warrant may be transferred only in whole, and not in part. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

6. LOST, STOLEN, MUTILATED OR DESTROYED
WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 7. AMENDMENT;
TERMINATION. This Warrant may be terminated, and any term of this Warrant may be amended or waived, with the written consent of the Company and the holder of the Warrant. 

8. NOTICES, ETC. All notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to the Holder at the addresses set forth on the first page of this Warrant or at such other addresses as the Company or Holder
may designate by ten (10) days advance written notice to the other parties hereto. 
 9.
ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 
 10. GOVERNING LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by the laws of the State of New York. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT
BLANK] 

  
 5 








 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer on the date set forth on the face of this Warrant. 

			
	Puma Biotechnology, Inc.
		
	By:	 	/s/ Charles R. Eyler
	Name:	 	Charles R. Eyler
	Title:	 	Senior Vice President, Finance and Treasurer
		
	Address:	 	 10940 Wilshire Boulevard, Suite 600
 Los Angeles, California 90024




  
 [Signature
Page to Warrant] 








 NOTICE OF EXERCISE 
 TO: Puma Biotechnology, Inc. 
 (1)
 ̈ The undersigned hereby elects to purchase                  shares of Common Stock of Puma Biotechnology,
Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

       ̈ The undersigned hereby elects to purchase
                 shares of the Common Stock of the Company pursuant to the terms of the cashless exercise provisions set forth in Section 2.2 of the attached
Warrant, and shall tender payment of all applicable transfer taxes, if any. 
 (2) Please issue a certificate or
certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below: 
  

 
 (Name)

  
  

 
  

(Address) 

(3) The undersigned represents that (i) the aforesaid shares of Common Stock are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in
making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests;
(iv) the undersigned understands that the shares of Common Stock issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a
specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered
under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid shares of Common Stock may not
be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the
availability of current information to the public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the
aforesaid shares of Common Stock unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the
undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 








					
			
	  	 		 	  
	(Date)	 		 	(Signature)
			
	 	 		 	  
		 		 	(Print name)








 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 FOR VALUE RECEIVED, the foregoing Warrant and all rights
evidenced thereby are hereby assigned to 
  

			
	Name:  	  	 
		  	(Please Print)

  

			
	Address:  	  	 
		  	(Please Print)     

 Dated:
                         

			
		
	 Holder’s

Signature:
	 	 


			
		
	 Holder’s

Address:
	 	 

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the
Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.